<DOC>
	<DOCNO>NCT01806298</DOCNO>
	<brief_summary>This open-label , single-arm , multicenter , Phase 4 study explore immunogenicity liquid formulation Saizen® subject Adult Growth Hormone Deficiency ( AGHD ) , growth hormone ( GH ) treatment-naïve prior GH treatment GHD stop least 1 month prior Screening contraindication use GH .</brief_summary>
	<brief_title>An Open-label Phase 4 Study Explore Immunogenicity Liquid Formulation Saizen® Subjects With Adult Growth Hormone Deficiency ( AGHD )</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Male female subject , 1865 year age , inclusive , time signature inform consent Documented AGHD i.e . childhood onset ( CO ) adult onset ( AO ) , either stimulation test describe GH Research Society 's 2007 guideline diagnosis treatment AGHD , Saizen® label , whichever stringent , confirm presence least 3 pituitary hormone deficiency IGF1 level reference range laboratory test perform . Stimulation test described 2007 GH Research Society guideline applicable subject underwent undergo stimulation test : Insulin Tolerance Test ( ITT ) glucagon stimulation test : Peak GH le 3 nanogram per milliliter ( ng/mL ) ; GHreleasing hormone ( GHRH ) plus arginine test , peak GH depend body mass index ( BMI ) : BMI le 25 kilogram per square meter ( kg/m^2 ) indicate peak GH le 11 ng/mL microgram per liter [ mcg/L ] ) . BMI 2530 kg/m^2 indicate peak GH le 8 ng/mL ( mcgg/L ) . BMI great 30 kg/m^2 indicate peak GH le 4 ng/mL ( mcg/L ) . Clonidine , ldopa , arginine alone acceptable stimulation test determine eligibility trial . Stimulation test remain Investigator 's subject 's physician 's responsibility , include selection GH assay . Saizen® label : Europe , one single test require ; Australia , 2 stimulation test show peak GH le 2.5 ng/mL require . The inclusion criterion choose base approved label Saizen® country trial implement , well respect current international guideline AGHD . There limit time prior Screening visit stimulation test ( ) , long documentation available stimulation test comply GH Research Society 2007 guideline , , need repeat test subject stop GH therapy prior Screening visit . No stimulation test require subject 3 pituitary hormone deficiency GH treatmentnaïve prior GH treatment AGHD stop least 1 month prior Screening visit . Whereas prior use GH permit , provide adequate washout period respect secure interpretation biomarkers , reason stop GH therapy neither safety efficacyrelated , documentation present source information Negative BAbs Screening visit sample Body mass index ( BMI , Weight kilograms / Height square meter ) measure Screening visit less equal 35 kilogram per square meter ( kg/m^2 ) Negative serum pregnancy test Screening woman childbearing potential subject lactate Understanding willingness subject comply procedure study Informed Consent form sign prior performance trialrelated activity Hypersensitivity active substance Saizen® excipients Evidence grow intracranial tumor include pituitary tumor , affect optic chiasm , require treatment ( surgery radiation ) within 6 month prior 12 month Screening visit Presence active malignancy , neoplasia evidence progression recurrence underlying tumor . In case history neoplasia preexist malignancy , tumor must inactive antitumor therapy complete prior start trial active Saizen® therapy . Proliferative preproliferative diabetic retinopathy Evidence chronic underlie disease within 6 month prior Screening visit concomitant medication would interfere subject compliance , evaluation trial result , compromise safety subject Severe hepatic renal failure could compromise interpretation IGF1 , : Alanine transaminase [ ALT ] aspartate transaminase [ AST ] great 3 * upper limit normal range ; Glomerular filtration rate ( GFR ) less 30 milliliter per minute ( mL/min ) Note : GFR calculate laboratory accord Modification Diet Renal Disease ( MDRD ) equation History antiGH antibody History presence autoimmune disease , Hashimoto 's disease Systemic Lupus Erythematosus ( SLE ) , immunosuppression regardless etiology , GH1 gene defect Absence effective contraception place Screening visit woman childbearing potential . Acceptable form effective contraception include : establish use oral ( great 2 month ) , inject , implanted hormonal method contraception , intrauterine device ( IUD ) , barrier method contraception , specifically , condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository Diabetes mellitus ( per American Diabetes Association 2010 guideline ) : either ) standard diabetes symptom random glucose great equal 200 milligram per deciliter ( mg/dL ) ( 11.1 millimolar per liter [ mmol/L ] ) ; ii ) fast plasma glucose great 126 mg/dL ( 6.99 mmol/L ) ; iii ) 2hour plasma glucose great equal 200 mg/dL ( 11.1 mmol/L ) oral glucose tolerance test ( OGTT ) ; iv ) glycosylated hemoglobin ( HbA1c ) great equal 6.5 percent Concomitant prior participation interventional trial within 30 day prior Screening visit Known alcohol drug addiction/dependency Has legal incapacity limited legal capacity Has receive anabolic steroid ( except gonadal steroid replacement therapy ) systemic corticosteroid ( except replacement dos ) within 3 month prior Screening visit Has receive substitutive therapy glucocorticosteroids , thyroid replacement , vasopressin , sex hormone less 3 month substitutive therapy stable ( , dose generally constant medical condition control ) 3 month prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Adult Growth hormone deficiency</keyword>
	<keyword>Saizen®</keyword>
	<keyword>Recombinant human growth hormone ( r-hGH )</keyword>
	<keyword>Somatropin</keyword>
</DOC>